US FDA approves Ionis therapy Zanvastro for rare brain disorder
The U.S. FDA approved Ionis Pharmaceuticals’ zilganersen (Zanvastro) to treat a rare genetic disorder affecting the brain’s white matter, with use for adults and pediatric patients.
The U.S. FDA on Thursday approved Ionis Pharmaceuticals' NASDAQ:IONS therapy for a rare genetic disorder affecting the brain's white matter, making it the first treatment cleared for the condition. Ionis' drug zilganersen, branded as Zanvastro, can be used to treat adults and pediatric patients.